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Abstract
Bst-2/Tetherin inhibits the release of HIV by tethering newly formed virus particles to the plasma membrane of infected
cells. Although the mechanisms of Tetherin-mediated restriction are increasingly well understood, the biological relevance
of this restriction in the natural target cells of HIV is unclear. Moreover, whether Tetherin exerts any restriction on the direct
cell-cell spread of HIV across intercellular contacts remains controversial. Here we analyse the restriction endogenous
Tetherin imposes on HIV transmission from primary human macrophages, one of the main targets of HIV in vivo. We find
that the mRNA and protein levels of Tetherin in macrophages are comparable to those in T cells from the same donors, and
are highly upregulated by type I interferons. Improved immunocytochemistry protocols enable us to demonstrate that
Tetherin localises to the cell surface, the trans-Golgi network, and the macrophage HIV assembly compartments. Tetherin
retains budded virions in the assembly compartments, thereby impeding the release and cell-free spread of HIV, but it is not
required for the maintenance of these compartments per se. Notably, using a novel assay to quantify cell-cell spread, we
show that Tetherin promotes the transfer of virus clusters from macrophages to T cells and thereby restricts the direct
transmission of a dual-tropic HIV-1. Kinetic analyses provide support for the notion that this direct macrophage-T cell spread
is mediated, at least in part, by so-called virological synapses. Finally, we demonstrate that the viral Vpu protein efficiently
downregulates the cell surface and overall levels of Tetherin, and thereby abrogates this HIV restriction in macrophages.
Together, our study shows that Tetherin, one of the most potent HIV restriction factors identified to date, can inhibit virus
spread from primary macrophages, regardless of the mode of transmission.
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Introduction
The replication of viruses can be inhibited by a number of
cellular proteins, collectively referred to as restriction factors [1].
In many cases, the expression of restriction factors is induced or
enhanced by type I interferons (IFN), which are upregulated
following infection with intracellular pathogens such as viruses.
The primate lentiviruses, including human immunodeficiency
viruses (HIV), are subject to restriction at multiple stages of their
life cycles [1]. In a number of these cases, viruses have evolved
mechanisms to abrogate the influence of specific cellular restriction
factors. Recently, HM1.24/CD317/Bst-2/Tetherin (Ensembl:
ENSG00000130303) was identified as a restriction factor of
particular significance, as the ability to antagonise Tetherin
appears to have been a major factor in the adaptation of SIVcpz
to man [2–4].
As implied by its name, Tetherin has the ability to tether HIV
particles to the surface of infected cells, and this function is
attributable to its unusual topology. Tetherin contains two
membrane anchors, an N-terminal transmembrane domain and
a C-terminal GPI-anchor [5,6]. During assembly and budding of
HIV particles at the plasma membrane (PM) of infected cells,
Tetherin can be incorporated into nascent virions via one of its
membrane anchors, leaving the second anchor in the PM, and
thereby preventing virus release into the extracellular milieu [7–9].
The failure to release free particles inhibits the cell-free spread of
HIV, which relies on the diffusion of released virus toward its
target cells.
HIV and related viruses have evolved mechanisms to overcome
Tetherin restriction and ensure their efficient propagation. In the
case of HIV-1 main (M) group viruses, the accessory protein Vpu
enhances lysosomal sorting and degradation of Tetherin, thereby
reducing the levels of the restriction factor at the cell surface, and
promoting HIV-1 release [10–12].
In addition to cell-free transmission, HIV can be transferred
across intercellular contacts. This cell-cell spread appears to be
significantly more efficient than cell-free propagation, and has been
proposed to occur via filopodial bridges, membrane nanotubes, and,
most prominently, virological synapses (VS) [13]. VS between T
cells are characterised by the recruitment of viral proteins and HIV
receptors to the cellular interface [14], however, little is known
about VS between HIV-infected macrophages and T cells [15,16].
Moreover, whether Tetherin also inhibits cell-cell spread of HIV, or
whether a direct contact between the infected and the target cell
eliminates the need for HIV to fully detach from its host cell,
remains controversial [17–23].
CD4+ T cells and macrophages are the main cellular targets of
HIV in vivo. Significantly, some aspects of viral replication vary
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with the target cell type. A prominent example is the site of virus
assembly: Whereas in T cells HIV assembles and buds at the cell
surface, in monocyte-derived macrophages (MDM) budding
intermediates are almost exclusively detected on deeply invagi-
nated PM domains [24,25], which we have termed Intracellular
Plasma Membrane-connected Compartments (IPMC) [26].
IPMCs have a neutral pH [27] and contain numerous molecules
typically found at the PM, including phosphatidylinositol-4,5-
bisphosphate [28], the tetraspanins CD9 and CD81, the
hyaluronan receptor CD44 [24], and focal adhesion proteins
including the integrins CD11b, CD11c, and CD18 [26]. Though
IPMCs are also present in uninfected MDMs, and thus not
induced by infection, HIV triggers changes in both the compo-
sition and morphology of the compartments: For example, IPMCs
in HIV-infected MDMs contain the tetraspanin CD63 [24] and
may be larger than in uninfected cells [29].
Given these variations in HIV replication in different cell types, it
is imperative to analyse the localisation, function and antagonism of
Tetherin specifically in macrophages. This notion is re-enforced by
a recent study suggesting important differences in Tetherin
antagonism in macrophages and non-monocytic cells, namely that
in MDMs Tetherin is only mildly induced by IFN, and that cell
surface Tetherin is inefficiently antagonised by Vpu [21].
Here we show that Tetherin expression in primary MDMs is as
sensitive to IFN as in primary T cells. At steady state, endogenous
Tetherin localises to the cell surface, the trans-Golgi network
(TGN), and IPMCs. Vpu efficiently antagonises cell surface
Tetherin in MDMs and, in cells devoid of Vpu, Tetherin retains
mature HIV particles in IPMCs, which may cause a virus particle-
induced expansion of the assembly compartments. Furthermore,
our experiments indicate that cell-cell transmission allows efficient
spread of HIV from MDMs to autologous CD4+ T cells. Using a
novel assay that strongly favours cell-cell over cell-free propaga-
tion, we show that Tetherin can restrict cell-cell transmission of
HIV from macrophages to T cells. Thus, our data indicate that
Tetherin has the potential to impose a major restriction to HIV
spread, regardless of the mode of transmission.
Results
Type I interferons upregulate Tetherin expression in
primary macrophages
Numerous studies have shown that type I IFNs induce the
expression of Tetherin in cell lines and primary T cells, but
whether this is also true for primary macrophages remains
controversial [21,30]. To determine whether type I IFNs induce
endogenous Tetherin expression in macrophages, we isolated
monocytes and CD4+ T cells from buffy coats of HIV-negative
donors, differentiated the monocytes into MDMs in vitro, and
proliferated the T cells in the presence of lectin and IL-2.
Subsequently, all cells were stimulated with 544 U/ml (2 ng/ml)
IFN-b for 24 h, and analysed by RT-qPCR and western blotting.
Increased mRNA levels of the IFN-induced gene IFIT1 in both
MDMs and T cells confirmed that the IFN-b preparation was
biologically active and induced the IFN pathway (Fig. 1A).
Notably, IFN-b treatment of MDMs upregulated both the
mRNA and protein levels of Tetherin by approximately one
order of magnitude (Fig. 1A,B). In autologous T cells, IFN-b
treatment increased the Tetherin levels two- to five-fold
(Fig. 1A,B).
We next examined the concentration dependence of the
Tetherin upregulation by type I IFNs. Following treatment of
MDMs with 20–500 U/ml IFN-b, we observed significant
increases in both IFIT1 and Tetherin mRNA levels (Fig. 1C), as
well as Tetherin protein levels (Fig. 1D), even at the lowest IFN-b
concentration tested. Together our data demonstrate that primary
MDMs upregulate Tetherin expression, even at low concentra-
tions of a type I IFN, to an extent comparable to autologous CD4+
T cells.
Tetherin localises to the cell surface, TGN, and IPMCs in
MDMs
We selected two commonly used, commercially available
antibodies to examine the cellular distribution of endogenously
expressed Tetherin in primary MDMs. Immunolabelling was
performed on live cells, as all Tetherin antibodies tested exhibited
reduced binding efficiency when applied after aldehyde fixation.
When we incubated unpermeabilised MDMs in antibody-
containing media on ice, then fixed and stained with a fluorescent
secondary antibody, endogenous Tetherin was readily detected on
the surface of primary MDMs (Fig. 2A). Consistent with an
increase in mRNA and overall protein levels (Fig. 1), the levels of
cell surface Tetherin were increased following IFN treatment
(Fig. 2A).
We next permeabilised MDMs and incubated them with
polyclonal antibodies against Tetherin and TGN46, or monoclo-
nal antibodies against Tetherin and CD9, on ice. In both cases
Tetherin was detected in two distinct intracellular locations: In
almost all cells Tetherin was found in spots (double arrows in
Fig. 2B,C), often distributed around the nucleus, which co-
localised with TGN46 (double arrows in Fig. 2B). Some MDMs
showed additional accumulations of Tetherin (arrowheads in
Fig. 2B,C), which co-stained for the IPMC protein CD9
(arrowheads in Fig. 2C). Also in permeabilised MDMs, Tetherin
levels were higher in IFN-stimulated than in untreated cells
(compare Fig. 2B,C to Fig. S1A,B).
We conclude that in primary MDMs, endogenous Tetherin
localises to the cell surface, TGN, and IPMCs, without any
obvious enrichment of the protein in IPMCs. This is consistent
with the notion that IPMCs are continuous with, and biochem-
ically similar to, the PM [24,25].
Author Summary
Tetherin is a cellular protein that inhibits (or restricts) a
broad range of enveloped viruses, including HIV, by
physically ‘‘tethering’’ nascent particles to the plasma
membrane of infected cells. CD4+ T cells and macrophages
are the main targets of HIV in vivo, and both cell types
express Tetherin. Although the mechanisms of Tetherin-
mediated restriction in model cell lines and T cells are
increasingly well understood, experimental data from
macrophages are sparse, and partially contradict observa-
tions made in other cell types. Here we investigate the
sensitivity of Tetherin expression to interferon, and the
subcellular localisation of the restriction factor in primary
human macrophages. We find that Tetherin inhibits HIV
release by retaining nascent particles in macrophage HIV
assembly compartments, and can also restrict the trans-
mission of HIV across intercellular contacts between
macrophages and T cells. Finally, we demonstrate that
the HIV protein Vpu efficiently counteracts Tetherin in
macrophages, and thereby ensures viral propagation. Our
results, together with other published data, show that
Tetherin can efficiently inhibit viral replication in both
major target cell types of HIV, regardless of the mode of
transmission. These data support the view that efficient
counteraction of Tetherin was a crucial factor for the
global spread of HIV.
Tetherin Can Restrict HIV Spread from Macrophages
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Vpu efficiently antagonises Tetherin in MDMs
To investigate whether HIV-1 Vpu antagonises endogenous
Tetherin in primary macrophages, we disrupted the Vpu gene of
the dual-tropic HIV-1 strain NL4.3-R3A (from hereon referred to
as R3A-(+)): R3A-(2) carries a start codon mutation, and R3A-
Udel an internal deletion in Vpu (Fig. 3A). We used both Vpu
mutants, R3A-(2) and -Udel, since MDMs infected with a Vpu
start codon-deleted HIV-1 have been suggested to express
increased levels of Env, which may affect Tetherin antagonism
and viral infectivity [31]. Western blot analyses confirmed that
Vpu was expressed in MDMs infected seven days after monocyte
isolation with R3A-(+) for seven days, but not in cells infected with
R3A-(2) or -Udel (Fig. 3B). Significant differences in Env
expression were not detected (Fig. 3B) and, consistently, single-
cycle infectivity assays indicated that MDM-derived R3A-(2) and
-Udel were as infectious as R3A-(+) (Fig. 3C).
We performed western blot analyses to test whether Vpu
antagonises Tetherin in primary MDMs. We found that Tetherin
levels in MDMs infected with R3A-(+) for seven days were
decreased compared to R3A-(2) and –Udel-infected cells (Fig. 3B),
showing that Vpu reduces the overall levels of endogenous
Tetherin in MDMs. The higher Tetherin levels detected in
infected compared to uninfected MDMs were most likely due to a
cellular IFN response. Consistently, western blotting showed that
Tetherin levels in R3A-infected MDMs were reduced when we
infected and cultured the cells in the presence of 1 mg/ml of an
IFN-a/b receptor antibody that has been shown to prevent
activation of the IFN receptor (Fig. S2, [32]).
To analyse the effects of Vpu on cell surface Tetherin in
MDMs, we immunolabelled R3A-infected cells in media contain-
ing Tetherin antibody on ice. Following fixation, the MDMs were
permeabilised and immunolabelled with a p24 Gag antiserum,
which also recognises cytosolic p55 Gag and thus allows the
unambiguous identification of infected cells. Compared to
uninfected cells of the same populations, the levels of cell surface
Tetherin were slightly reduced on R3A-(+)-infected, but signifi-
cantly increased on R3A-(2) and -Udel-infected MDMs (Fig. 4A).
Flow cytometry analyses confirmed these observations, with
Tetherin levels on R3A-(2) and –Udel-infected MDMs at least
two-fold higher than on R3A-(+)-infected cells (Fig. 4B,C).
Interestingly, the cell surface Tetherin levels on uninfected MDMs
within infected cell populations were higher than on completely
untreated cells (Fig. 4B,C). These observations are consistent with
our hypothesis that long-term HIV infection can trigger a cellular
Figure 1. Type I interferons upregulate Tetherin expression in primary macrophages. (A–B) Primary MDMs and autologous lectin/IL-2-
activated CD4+ T cells were stimulated for 24 h with 544 U/ml (2 ng/ml) IFN-b eight days post isolation from buffy coats. (A) IFIT1 and Tetherin mRNA
levels were determined by RT-qPCR and normalised to GAPDH. Bars represent the means 6 standard deviations (SD) from four donors relative to
untreated MDMs (2IFN, set at 1). (B) Tetherin protein levels were determined by western blot analysis of whole cell lysates containing equal amounts
of total protein. Numbers above each lane indicate the Tetherin band intensities relative to untreated MDMs (2IFN, set at 1). (C–D) MDMs were
stimulated for 24 h with 0–500 U/ml IFN-b eight days post isolation from buffy coats. (C) mRNA levels were determined as described for (A). Bars
represent the means 6 SD from three donors relative to untreated MDMs (set at 1). (D) Tetherin protein levels were determined by western blot
analysis of whole cell lysates.
doi:10.1371/journal.ppat.1004189.g001
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IFN response, which would lead to the secretion of IFNs and an
upregulation of Tetherin in surrounding cells. A cellular IFN
response could also explain the increased cell surface Tetherin
levels seen on R3A-(2) and –Udel-infected compared to
uninfected MDMs (Fig. 4B,C).
Together, our data show that Vpu reduces the overall levels
of endogenous Tetherin in MDMs. The high efficiency of
Tetherin labelling we achieved allowed us to also detect Vpu-
induced downregulation of the restriction factor from the cell
surface.
Tetherin retains HIV in the IPMCs of MDMs
We next sought to examine if and where Tetherin retains HIV
on primary macrophages. When we infected MDMs with R3A for
seven days and performed western blot analyses of the cell lysates,
we found significantly more p24 Gag associated with R3A-(2) and
Figure 2. Tetherin localises to the cell surface, TGN, and IPMCs. (A) Untreated MDMs (2IFN), or MDMs treated for 24 h with 544 U/ml IFN-b (+
IFN), were incubated for 1 h on ice in media containing 10 mg/ml polyclonal Tetherin (THN) antibody (B02P), or VSV-G antibody as a negative control.
Cells were fixed and labelled with a fluorescent secondary antibody. (B–C) IFN-b-treated MDMs were incubated for 20 min on ice with 10 mg/ml
polyclonal Tetherin antibody (B02P) and 2.5 mg/ml anti-TGN46, or with 10 mg/ml monoclonal Tetherin antibody (M15) and 2 mg/ml anti-CD9, in the
presence of 0.05% saponin. Cells were fixed and labelled with fluorescent secondary antibodies. Arrowheads point at structures reminiscent of IPMCs,
double arrows indicate TGN-like staining patterns. All images are single confocal sections. Scale bars = 10 mm.
doi:10.1371/journal.ppat.1004189.g002
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–Udel, than with R3A-(+)-infected cells (Fig. 5A). p24 and p17
Gag are predominantly found in mature HIV particles, matura-
tion involving the cleavage of p55 Gag during or shortly after
budding. The increased p24 Gag levels therefore indicated that, in
the absence of Vpu, budded HIV particles were retained on
MDMs, presumably by the elevated levels of Tetherin. Consis-
tently, when we depleted MDMs of Tetherin by RNAi, only low
levels of p24 Gag were associated with R3A-(+), -(2) and –Udel-
infected cells (Fig. 5B).
To directly test whether Tetherin-mediated retention of virus
impedes the release and thus cell-free spread of HIV from primary
macrophages, we quantified virus released from R3A-(+), -(2), and
–Udel infected MDMs. p24 ELISAs showed that HIV release into
the supernatant was lower in the absence of Vpu than in its
presence (Fig. 5C), and this restriction was overcome by depleting
MDMs of Tetherin (Fig. 5D).
To examine the localisation of retained HIV particles, we
immunostained R3A-infected MDMs with a p17 Gag antibody
that specifically labels mature HIV particles, and a p24/p55 Gag
antiserum to identify infected cells. Consistent with the western
blot analyses, more p17 Gag was associated with R3A-(2) and –
Udel than with R3A-(+)-infected MDMs (Fig. 6A,B), and
quantification of this effect by flow cytometry revealed a two- to
three-fold difference in the p17 Gag mean fluorescence intensities
(Fig. S3). Most retained HIV was intracellular (Fig. 6A,B), and co-
staining experiments showed that both in the presence and
absence of Vpu the intracellular virus co-localised with the IPMC-
enriched tetraspanin CD9 (Fig. 6A), but not with the lysosomal
marker LAMP1 (Fig. 6B).
Thus, in the absence of Vpu, endogenous Tetherin retains
mature HIV in the IPMCs of primary MDMs, and restricts cell-
free viral spread.
Tetherin is not required to maintain IPMCs
Tetherin-mediated retention of HIV in the IPMCs of MDMs
likely leads to a passive expansion of the assembly compartments,
but it is unclear whether the restriction factor is required for the
integrity of IPMCs per se. When we co-stained R3A-infected
Figure 3. Vpu efficiently antagonises Tetherin in MDMs. (A) Schematic representation of the R3A molecular clones used in this study. R3A-(+)
expresses a Vpu protein, R3A-(2) and -Udel do not. (B) MDMs were infected with R3A-(+), -(2), or -Udel for seven days, lysed, and analysed by western
blotting. The Tetherin band intensities were quantified and normalised to the c-adaptin levels, respectively. Bars represent the means 6 SD of
duplicate samples from three donors relative to R3A-(+) (set at 1). (C) Cell-free culture supernatants from R3A-infected MDMs were collected, p24 Gag
levels adjusted, and single-cycle infectivities determined using TZM-bl cells. Bars represent the means 6 SD of triplicate samples from four donors
relative to R3A-(+) (set at 100%).
doi:10.1371/journal.ppat.1004189.g003
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MDMs for Tetherin, CD9 and p17 Gag, as expected, Tetherin
was found to accumulate in the IPMCs of R3A-(2) and –Udel-
infected cells (Fig. 7A). Tetherin levels in the IPMCs of R3A-(+)-
infected cells were lower than in R3A-(2) or -Udel-infected
MDMs, even when IPMCs of similar sizes, which contained
similar amounts of virus, were compared (Fig. 7A). These
observations indicated that Vpu reduces Tetherin levels also in
IPMCs, but that the assembly compartments are maintained even
at low concentrations of the restriction factor. Consistently, when
we treated uninfected MDMs with Tetherin or control siRNA and
quantified the proportion of cells with intracellular co-localisation
of the IPMC proteins CD9 and CD81, around 40% of MDMs
contained IPMCs regardless of the Tetherin levels (Fig. 7B–D).
Overall, these data show that Tetherin is not required to maintain
IPMCs in primary MDMs.
HIV is transmitted from MDMs to T cells via virological
synapses
To determine whether Tetherin restricts cell-cell spread of HIV
from macrophages to autologous CD4+ T cells, we initially
Figure 4. Vpu antagonises cell surface Tetherin in MDMs. (A) R3A-infected MDMs were incubated for 1 h on ice in media containing 10 mg/ml
polyclonal Tetherin (THN) antibody (B02P). Cells were fixed, permeabilised, labelled with a p24/p55 Gag antiserum, and stained with fluorescent
secondary antibodies. Asterisks mark infected cells. Single confocal sections are shown. Scale bars = 10 mm. (B–C) Cell surface Tetherin on uninfected
and R3A-infected MDMs was labelled as described for (A), uninfected MDMs were incubated with VSV-G antibody as a negative control, and all cells
were analysed by flow cytometry. Uninfected cell populations were left ungated, infected cell populations gated on the uninfected or infected
subpopulations. (B) shows the results of a representative experiment, the bars in (C) represent the average Tetherin mean fluorescence intensities
(MFI) 6 SD from three donors relative to the gated, uninfected subpopulations (set at 100%).
doi:10.1371/journal.ppat.1004189.g004
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examined the mode, kinetics, and efficiency of the direct MDM-T
cell transmission.
Immunofluorescence studies showed that primary CD4+ T cells
readily associated with uninfected as well as HIV-1 BaL-infected
MDMs within 2.5 h of co-culture (Fig. S4). When T cells were
associated with infected MDMs, clusters of p17 Gag were
occasionally found at the intercellular junctions, and in some
cases CD4 co-clustered as well (Fig. 8A and Fig. S4). Junctions
between infected MDMs and uninfected T cells characterised by
an accumulation of mature HIV particles are from hereon referred
to as virological synapses (VS). It has been suggested that MDM-T
cell VS form by re-localisation of virus-filled IPMCs in MDMs to
Figure 5. Tetherin retains HIV on infected MDMs. (A) MDMs were infected with R3A-(+), -(2), or -Udel for seven days, lysed, and analysed by
western blotting. Note that the c-adaptin blot from this donor is shown in Fig. 3B. The p24 Gag band intensities were quantified and normalised to
the p55 Gag levels. Bars represent the means6 SD of duplicate samples from three donors relative to R3A-(+) (set at 1). (B) MDMs were infected with
R3A and transfected with control or Tetherin siRNA the next day. Cells were lysed six days later and analysed by western blotting. (C) p24 Gag
concentrations in cell-free culture supernatants from R3A-infected MDMs were determined using ELISAs. Bars represent the means 6 SD of triplicate
samples from three donors relative to R3A-(+) (set at 100%). p values were calculated using a paired Student’s t-test before normalisation. (D) p24 Gag
concentrations in cell-free culture supernatants from R3A-infected, siRNA-treated MDMs were determined using ELISAs. Bars represent the means 6
SD of triplicate samples from a representative experiment, relative to control RNAi/R3A-(+) (set at 100%).
doi:10.1371/journal.ppat.1004189.g005
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the MDM-T cell interface [16]. We observed that the IPMC
proteins CD9 (Fig. S5A) and CD81 (Fig. S5B), as well as the b2
integrin CD18 (Fig. S5C), were also occasionally enriched at VS.
To determine the kinetics of MDM-T cell association and VS
formation, we co-cultured BaL-infected MDMs with uninfected
autologous CD4+ T cells, and fixed and immunostained the cells at
30 min intervals from 0 min (no T cells added) to 240 min.
Though T cells rapidly associated with MDMs, few VS were
detected after the first 30 min of co-culture (Fig. 8B). The
proportion of infected MDMs with VS gradually increased
between 30 and 120 min, and then remained relatively constant
(Fig. 8B).
These observations suggested that the transfer of HIV from
MDMs to T cells is mediated by VS. However, successful infection
requires the fusion of viral particles with a target cell membrane,
and reverse transcription of viral RNA genomes. We used qPCR
to quantify the levels of HIV Gag DNA in T cells after co-culture
with BaL-infected MDMs. Low levels of HIV DNA were detected
in T cells after 1 and 2.5 h of co-culture (Fig. 8C), when VS
formation had already peaked (Fig. 8B), but significantly higher
levels were detected after 6 h (Fig. 8C). The reverse transcriptase
inhibitor nevirapine (NVP) prevented HIV DNA accumulation,
confirming that the qPCR assay detected only newly synthesised
viral DNA (Fig. 8C).
We conclude that on co-culture of CD4+ T cells with autologous
MDMs, T cell association with MDMs precedes VS formation,
which in turn precedes the efficient MDM to T cell transfer of
HIV, and T cell infection. This suggests that VS formation is an
active process that plays a major role in the transmission of HIV
from macrophages to T cells.
Finally, we determined the relative efficiencies of cell-cell and
cell-free transmission of HIV. T cells co-cultured for 6 h with BaL-
or R3A-infected MDMs contained at least ten times more HIV
DNA than T cells incubated with cell-free virus released by the
same MDMs during the preceding 6 h period (Fig. 8D and Fig.
S6).
Tetherin restricts cell-cell transmission of a dual-tropic
HIV-1 from macrophages to T cells
Having shown that short-term co-cultures strongly favour cell-
cell over cell-free HIV transmission (Fig. 8D and Fig. S6), we used
this assay to study whether endogenous Tetherin can restrict the
direct cell-cell spread of HIV from primary MDMs to autologous
CD4+ T cells. Following 6 h of MDM/T cell co-culture, the T
cells were washed off the MDMs with PBS, incubated further, and
their overall infection assayed by western blotting (Fig. 9A). This
approach allowed us to accurately determine the levels of T cell-
associated p55 Gag, which is important when comparing the
infection levels of cells that express, or do not express Vpu, as
Tetherin alters the ratios of p24/p55 Gag (Fig. 5A). When we co-
cultured T cells with R3A-(+), -(2), and –Udel-infected MDMs,
and continued to incubate the T cells separately for two days, only
the Vpu-containing R3A-(+) efficiently infected the T cells
(Fig. 9B). This observation indicated that Tetherin can inhibit
cell-cell transmission of HIV.
Control experiments were performed to confirm that the p55
Gag detected in the T cells after the co-culture was synthesised in
these cells, and did not derive from the MDMs. As expected, no
p55 Gag was detected in T cells that were harvested immediately
after the co-culture with MDMs, or exposed to NVP during and
after the co-culture, and no viral or cellular proteins were detected
in the recovered media when the T cells were omitted (Fig. 9B).
Further control experiments showed that Vpu expression in R3A-
infected MDMs did not influence their adhesion to T cells (Fig.
S7).
To demonstrate that Tetherin inhibits the transmission of HIV-
1 from MDMs to T cells, and not the subsequent replication of the
virus in T cells, we limited replication to a single round, either by
adding NVP to the T cells immediately after the co-culture, or by
harvesting the T cells after only one day. We still observed efficient
infection of the T cells only with R3A-(+) (Fig. 9C). Notably, when
we depleted R3A-infected MDMs of Tetherin before the co-
culture (Fig. 9A), T cell infection with the Vpu-negative R3A-(2)
and –Udel was rescued (Fig. 9D).
Tetherin may restrict MDM-T cell transmission by
promoting the transfer of HIV clusters
We next sought to investigate the mechanism by which Tetherin
inhibits cell-cell transmission of HIV from macrophages to T cells.
Hardly any p17 Gag accumulations were observed between R3A-
infected MDMs and T cells, rendering us unable to quantify VS
(Fig. S8A). We hypothesise that the p17 Gag accumulations at
MDM-T cell interfaces are more transient when MDMs are
infected with the dual-tropic R3A than with the CCR5-tropic
BaL, as significantly more primary CD4+ T cells express CXCR4
than CCR5 at their surface (Fig. S8B,C), which may accelerate
R3A entry into T cells.
We next used Gag qPCR to investigate the early events of T cell
infection following cell-cell transmission from MDMs. Intriguingly,
similar levels of HIV DNA were detected in T cells immediately
after their co-culture with R3A-(+), -(2) or -Udel-infected MDMs,
although only R3A-(+)-infected T cells from the same experimen-
tal samples contained significant HIV protein levels two days later
(Fig. 10A). Addition of NVP to the T cells during the co-culture
inhibited the accumulation of HIV DNA (Fig. 10A). Since high
Tetherin levels retain mature HIV particles on MDMs, we
hypothesised that during cell-cell transmission in the absence of
Vpu, infectious virus clusters may be transferred from MDMs to T
cells, and lead to high HIV DNA levels in a few T cells, but overall
a low proportion of infected cells. To test this hypothesis, we co-
cultured R3A-(+), -(2), or –Udel-infected MDMs with T cells,
immunostained the T cells for p17 Gag immediately after the co-
culture and analysed them by flow cytometry. We found that T
cells carried significantly more HIV clusters in the absence of Vpu
than in its presence, and the difference was particularly
pronounced for medium and large clusters (Fig. 10B,C). More-
over, when we incubated the T cells for longer times following
their co-culture with MDMs, we found that R3A-(+) DNA
accumulated much faster than R3A-(2) or –Udel DNA, and
significantly higher R3A-(+) DNA levels were detected in the T
cells after three days (Fig. 11A). Consistently, when we quantified
the proportion of HIV-infected T cells by flow cytometry five days
after their co-culture with infected MDMs, only T cells that had
been co-cultured with R3A-(+)-infected MDMs contained a
significant proportion of Gag-positive cells (Fig. 11B,C).
Together these data show that only in the presence of Vpu, do
MDMs transmit sufficient HIV to initiate a spreading infection in
T cells. In the absence of Vpu, endogenous Tetherin inhibits the
cell-cell transmission of HIV from primary MDMs to autologous
Figure 6. In the absence of Vpu, HIV accumulates in IPMCs. (A–B) MDMs were infected with R3A-(+),-(2), or -Udel for seven days, fixed, and
immunostained for the indicated proteins. Single confocal sections are shown. Scale bars = 15 mm.
doi:10.1371/journal.ppat.1004189.g006
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CD4+ T cells, presumably by promoting the transfer of infectious
virus clusters to a limited number of target cells.
Discussion
In recent years, an increasing number of cellular proteins that
inhibit, or restrict, virus replication have been identified. Of these,
Tetherin (HM1.24/CD317/Bst-2) stands out in that its efficient
counteraction appears to have been crucial for the global spread of
HIV [4]. Though SIV has crossed the species barrier from apes to
man on at least four different occasions, giving rise to HIV-1 group
M, N, O and P viruses, only group M HIVs, which have a fully
functional antagonist of Tetherin, the Vpu protein, have spread
globally [4,33–35].
In the absence of an antagonist, Tetherin restricts cell-free
propagation of HIV by physically linking mature virus particles to
the surface of infected cells [2,3,7,8]. Tetherin can also activate the
NFkB signalling pathway, which may contribute to restriction
[36]. A recent study showed that in addition to the full-length
protein, cell lines and primary cells express a short isoform of
Tetherin that lacks 12 N-terminal residues, is less sensitive to
antagonism by Vpu, and cannot activate the NFkB pathway [37].
However, there is an increasingly strong view that direct cell-cell
transmission of HIV is more efficient than cell-free propagation
[13]. In this study we found that Tetherin can also restrict cell-cell
transmission of HIV from macrophages to CD4+ T cells.
Macrophages, including neural microglia, are targets of HIV
infection in vivo and, at least partially, responsible for HIV-
associated dementia and neuropathy [38]. Several aspects of HIV
replication in macrophages differ from other cell types: Whereas T
cells are rapidly depleted early after HIV infection, macrophages
appear to be more resistant to the cytopathic effects of HIV, and
can survive for weeks to months following infection. This has led to
the suggestion that macrophages may serve as reservoirs for HIV,
particularly at the late stages of AIDS, when T cells are largely
depleted [38].
Although both T cells and macrophages are major targets for
HIV infection, the cell biology of virus replication in macrophages
can differ to that seen in T cells. In infected tissue culture
macrophages at least, the assembly of new virions is thought to
occur predominantly in IPMCs (or virus containing compartments
[VCC]), and not at the cell surface as seen in T cells [24,25]. Some
controversy exists as to whether IPMCs can transiently detach
from the PM [39], but most data indicate that the majority of these
compartments are contiguous with the cell surface [24,25,28].
IPMCs are thought to be largely impermeable to antibodies
[40,41]. In vivo, this may shield sites of HIV assembly from
circulating neutralising antibodies, which may help HIV-infected
macrophages to evade detection by the host immune system, and
contribute to their long-term survival. Virus assembly and budding
into IPMCs may also allow HIV release to be regulated, for
example through VS [15,16].
Because of the influence of Tetherin on the pandemic spread of
HIV, the contribution of macrophages to HIV pathogenesis, and
the cell type-specific differences in HIV replication, it is imperative
to understand the effects of Tetherin on HIV replication in
macrophages. To address this issue, we have relied almost entirely
on primary human cells, i.e. macrophages derived from monocytes
isolated from HIV-negative donors, and CD4+ T cells separated
from the peripheral blood mononuclear cells of the same donors.
This approach ensured that we studied cells expressing endoge-
nous levels of Tetherin, thus avoiding possible effects of aberrant
glycosylation and trafficking inherent to overexpression [7].
Moreover, we relied exclusively on HIV Env-mediated infection,
avoiding possible artefacts that might result from the use of
aberrant entry pathways and/or high multiplicities of infection of
pseudotyped HIV.
By analysing both mRNA and protein, we found that type I
IFNs upregulate the expression of Tetherin in MDMs even at low
concentrations, and to an extent similar to that seen in IFN-treated
T cells (Fig. 1). In the course of our study, we observed striking
differences between western blots of Tetherin under non-reducing
and reducing conditions: When we lysed MDMs in Laemmli
buffer devoid of any reducing agent, Tetherin appeared as a
prominent smear at ,60–100 kDa and a weaker smear at
,40 kDa (Fig. S9). These bands likely correspond to dimeric
and monomeric forms of glycosylated Tetherin, respectively.
Consistently, both bands completely disappeared upon Tetherin
RNAi (Fig. 5B, 9D). Blotting the same lysates in the presence of 2-
mercaptoethanol revealed a sharp, prominent band at ,24 kDa,
and a higher molecular weight smear appeared only with longer
exposures of the blots (Fig. S9). We propose that the sharp band
seen after reduction masks changes in Tetherin levels observed
under non-reducing conditions, and may explain why a recent
study found only moderate upregulation of Tetherin protein when
treating MDMs with high levels of IFN [21].
Our immunofluorescence studies show that in uninfected
MDMs, endogenous Tetherin localises to the cell surface, IPMCs,
and TGN, without any obvious enrichment in IPMCs (Fig. 2). In
cells infected with Vpu-deleted HIV, Tetherin retains virus in
IPMCs (Fig. 6), which may result in a passive enrichment of
Tetherin (Fig. 7A). As we know that accumulating virus expands
IPMCs [29], tethered HIV will also cause a passive expansion of
the size of the assembly compartments. These data, and the
observation that less mature HIV is associated with MDMs
following Tetherin RNAi (Fig. 5B), explain why a recent study
detected smaller and fewer virus-filled IPMCs when depleting
MDMs of Tetherin [21]. When investigated on uninfected
MDMs, where IPMCs are not passively expanded by accumulat-
ing virus, we find no evidence that Tetherin plays an active role in
the formation and/or maintenance of IPMCs (Fig. 7).
The improved Tetherin immunofluorescence labelling we
achieved allowed us to detect cell surface Tetherin on MDMs,
and Vpu-induced downregulation (Fig. 2A, Fig. 4), which was not
observed in a recent study [21]. Low cell surface levels of Tetherin
in the presence of Vpu corresponded with decreased overall levels
(Fig. 3B). However, even in the presence of Vpu, HIV-infected
MDM populations showed higher overall Tetherin levels than
uninfected cells (Fig. 3B). We believe that this is caused by an IFN
response to long-term HIV infection. Vpu would partially
Figure 7. Tetherin is not required to maintain IPMCs. (A) IFN-b-treated MDMs were incubated for 20 min on ice with 10 mg/ml monoclonal
Tetherin antibody (M15) and 2 mg/ml anti-CD9 in the presence of 0.05% saponin. Cells were fixed, labelled with anti-HIV-1 p17 Gag, and
immunostained with fluorescent secondary antibodies in the presence of 0.1% Triton X-100. Scale bars = 10 mm. (B) MDMs were left untreated, or
transfected with Tetherin or control siRNA for seven days. All cells were fixed and immunostained for CD9 and CD81. Arrowheads point at examples
of structures identified as IPMCs. All images are single confocal sections. Scale bar = 10 mm. (C) Parallel cultures to the ones shown in (B) were lysed
seven days after siRNA treatment and analysed by western blotting. (D) MDMs were treated as described for (B), and the proportion of cells showing
any intracellular CD9/CD81 co-localisation was quantified on nine random confocal stacks for each condition. Between 255 and 407 cells were
counted for each data point. The graphs show the means 6 SD from five donors, and each donor is represented by differently shaped data points.
doi:10.1371/journal.ppat.1004189.g007
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counteract the increased Tetherin expression in infected cells, but
released IFN would lead to high Tetherin levels in the uninfected
MDMs of the same population. In this situation, western blot
analysis would show an increase in the overall Tetherin levels in
the population (Fig. 3B), whereas flow cytometry, gated to the
infected cells only, would detect decreased levels of cell surface
Tetherin (Fig. 4B,C). Consistently, cell surface levels of Tetherin
on uninfected cells within infected MDM populations were higher
than on completely untreated cells (Fig. 4B,C), and Tetherin levels
in R3A-infected MDMs decreased when we prevented activation
of the IFN-a/b receptor using antibodies (Fig. S2). Nevertheless,
our data show that HIV-1 Vpu efficiently antagonises endogenous
Tetherin in primary macrophages. Residual Tetherin restriction
may occur even in the presence of Vpu, as even less HIV was
retained (Fig. 5B), and more released (Fig. 5D), upon Tetherin
RNAi than in the presence of Vpu alone, but these differences
were less pronounced and not statistically significant.
VS between infected and uninfected cells have been suggested
to facilitate the cell-cell spread of HIV [13]. Although VS between
infected macrophages and T cells have been observed [15],
evidence that these are involved in HIV transmission is missing. In
this study, we report that structures reminiscent of VS form
between HIV-infected MDMs and autologous CD4+ T cells
(Fig. 8A, Fig. S4). The temporal appearance of these VS is
consistent with them mediating cell-cell transmission of virus, i.e.
they succeed MDM-T cell interaction, but precede the appearance
of HIV DNA in T cells (Fig. 8B,C). However, we cannot rule out
the possibility that other modes of cell-cell transfer, including
filopodial bridges and membrane nanotubes, may also contribute
to HIV transmission from macrophages to T cells.
We have developed a novel co-culture assay to examine the
effects of Tetherin on the cell-cell spread of HIV from infected
MDMs to T cells (Fig. 9A). In contrast to other studies, in which
infected and target cells were co-cultured for up to several days
[18,19,21–23], we limited the co-culture to only 6 h. This
approach prevented the accumulation of cell-free virus, and thus
strongly favoured cell-cell transmission (Fig. 8D, Fig. S6). Our
assay was sensitive enough to reliably detect even low levels of
infection, as seen in our experiments as a result of the short co-
culture and the use of primary cells. Finally, and again in contrast
to other studies [17,18,21,22], our assay allowed us to detect
infection using the levels of p55 Gag only.
Using this assay, we found that Tetherin can inhibit cell-cell
transmission of HIV from MDMs to autologous CD4+ T cells, and
this effect was independent of whether or not the virus was allowed to
replicate in the T cells (Fig. 9, Fig. 10, Fig. 11). On-going replication
led to increasing levels of T cell infection at one and two days after
their co-culture with R3A-(+)-infected MDMs, and intermediate
infection levels were detected when NVP was added to the T cells for
the two day-incubation after the co-culture. However, efficient T cell
infection always depended on the downregulation of Tetherin in the
MDMs, either by Vpu (Fig. 9B, C), or by RNAi (Fig. 9D).
Immediately after their co-culture with R3A-(+), -(2) or –Udel-
infected MDMs, all T cells contained similar levels of HIV DNA,
but only in the presence of Vpu was significant infection detected
two days later (Fig. 10A). We hypothesise that, in the absence of
Vpu, high Tetherin levels on MDMs promote the transfer of
infectious clusters of HIV to T cells, which lead to high HIV DNA
levels in a few T cells, but overall a low proportion of infected cells.
Consistently, immediately after their co-culture with infected
MDMs, we detected more and larger HIV clusters on T cells in
the absence of Vpu than in its presence (Fig. 10B,C), and when
HIV DNA and protein levels were assessed three or five days later,
respectively, significantly more HIV DNA and a higher proportion
of infected T cells were detected when Tetherin was antagonised
by Vpu (Fig. 11). These observations are consistent with a previous
study, which showed that in the absence of Vpu, HIV clusters are
transferred from infected to uninfected T cells, but fail to initiate
productive infection [17]. Notably, similar DNA levels in T cells
immediately after their co-culture with infected MDMs confirmed
that R3A-(2) and -Udel are as infectious as R3A-(+).
Recent evidence suggests that an accumulation of HIV DNA in
activated or resting T cells may trigger innate immune responses,
and lead to cell death by apoptosis or pyroptosis, respectively [42–
44]. Therefore, during macrophage-T cell transmission of Vpu-
deficient HIV, the accumulation of viral DNA in target cells may
promote cell death, which could contribute to inefficient T cell
infection. However, when we labelled T cells with a dead cell stain
0, 6, 18, and 30 h after their co-culture with HIV-infected MDMs,
we did not detect increased T cell death in the absence of Vpu
(Fig. S10).
In vitro at least, cell-cell transmission of HIV is thought to be
more efficient than cell-free propagation. The high evolutionary
pressure on SIV/HIV to maintain a Tetherin antagonist suggests
that Tetherin inhibits both the cell-cell and cell-free spread of
HIV. Although our data are consistent with this notion, there may
be cell type-specific differences. For example, VS between T cells
are thought to involve polarised budding of HIV into the synaptic
cleft [14], whereas VS between monocytic cells and T cells may
form by re-localisation of virus-filled IPMCs to the site of VS
formation [16]. HIV that accumulates in IPMCs before reaching
the VS may be more susceptible to clustering by Tetherin than
newly budded virions in the T cell-T cell synapse. Consistently,
most studies using monocytic cells, i.e. MDMs and monocyte-
derived dendritic cells, found that Tetherin restricts cell-cell
transmission of HIV [21,22]. Similarly, Vpu-deficient HIV-1, as
well as virus strains encoding mutated Vpu proteins, have been
shown to inefficiently spread in macrophage populations [45].
Whether Tetherin also inhibits T cell-T cell spread remains
controversial. A recent study suggested that Tetherin increases the
number of VS formed between T cells, and thereby enhances
target cell infection [18]. Consistently, in a previous study a Vpu-
deficient HIV-1 clone emerged during selection of viruses that
efficiently spread in a rapid-turnover culture of T cells [46].
Figure 8. HIV is transmitted from MDMs to T cells via virological synapses. (A) MDMs were infected with HIV-1 BaL for seven days, co-
cultured with autologous CD4+ T cells for 2.5 h, fixed and immunostained for the indicated proteins. Arrows indicate VS. Scale bars = 10 mm. (B) BaL-
infected MDMs were co-cultured with autologous T cells for the indicated times, fixed, and immunostained for p17 Gag and CD4. No T cells were
added to a control sample of MDMs (0 min). The proportion of infected MDMs that associated with T cells (black+grey bars), and formed VS (black
bars) was counted on seven random confocal images with a total of 146–208 infected MDMs for each time point. (C) BaL-infected MDMs were co-
cultured with autologous T cells for the indicated times, the T cells were washed off the MDMs, and Gag DNA levels in the T cells were quantified by
qPCR. As controls, T cells were incubated for 6 h with uninfected MDMs (uninf), or with infected MDMs in the presence of 500 nM NVP (6 h/NVP). (D)
Autologous CD4+ T cells were incubated for 6 h with BaL-infected MDMs, or with cell-free supernatants collected from the same MDMs during the
preceding 6 h period. All T cells were collected and Gag DNA levels in the T cells quantified by qPCR. (C–D) Gag DNA levels were normalised to
GAPDH. For cell-cell transmission experiments, the levels of contaminating MDM-derived Gag and GAPDH DNA were subtracted from the total DNA
levels. Graphs show the means 6 SD of triplicate samples from a representative experiment relative to 6 h (set at 100%), or cell-free (set at 1).
doi:10.1371/journal.ppat.1004189.g008
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Figure 9. Tetherin restricts cell-cell transmission of a dual-tropic HIV-1 from MDMs to T cells. (A) Schematic outline of the assay used to
quantify cell-cell transmission from MDMs to autologous CD4+ T cells. (B) R3A-(+), -(2), or -Udel-infected MDMs, or uninfected control MDMs, were co-
cultured with autologous CD4+ T cells for 6 h, the T cells were washed off the MDMs with PBS and lysed immediately (0 days), or after another two
day-incubation (2 days). As a control, 500 nM NVP was added to parallel MDM-T cell co-cultures, and to the T cells after the co-culture (T cells/NVP
during and after co-culture). No T cells were added to infected MDMs, and the culture supernatants treated as the T cells, as another control (no T
cells). All T cell lysates were analysed by western blotting. (C) T cells were co-cultured with R3A-infected MDM for 6 h, separated from the MDMs, and
incubated for another zero to two days (0–2 days), or for two days in the presence of 500 nM NVP (2 days/NVP after co-culture). The T cells were lysed
and analysed by western blotting. Note that parallel cultures of the MDMs used for the experiments in (B) and (C) were analysed by western blotting
to confirm equal infection levels (Fig. S11). (D) MDMs were infected with R3A and transfected with control (control RNAi) or Tetherin (Tetherin RNAi)
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However, other studies argue that Tetherin restricts the direct T
cell-T cell transmission of HIV. In one study, clusters of Vpu-
deficient HIV particles were seen to be transferred from infected to
uninfected cells, but impaired in their ability to fuse with and thus
infect target cells [17]. Still, Tetherin did not seem to perturb the
formation of VS [17].
Overall our study shows that in MDMs Tetherin is upregulated
even by low concentrations of type I IFNs, and localises to the cell
surface, TGN, and IPMCs. Vpu efficiently antagonises Tetherin
and, in the absence of Vpu, mature HIV accumulates in IPMCs.
Although Tetherin-bound virus may expand IPMCs, there is no
indication that Tetherin plays an active role in the formation and/
or maintenance of the HIV assembly compartments. Finally, we
find that Tetherin can restrict cell-cell transmission of HIV from
MDMs to T cells, and the assay applied in this study may help
elucidate whether the restriction factor also inhibits transmission
between other cell types. Thus, this study provides crucial insight
into one of the most potent HIV restriction factors identified to
date, in one of the main target cells for HIV infection.
Materials and Methods
Reagents and antibodies
Tissue culture media and supplements were purchased from
Life Technologies (Paisley, UK), Fetal Calf Serum (FCS) Gold
from PAA (Yeovil, UK), human AB serum from PAA and Sigma-
Aldrich (Dorset, UK), tissue culture plastic from Thermo Fisher
Scientific (Waltham, USA) and TPP (Trasadingen, Switzerland),
and chemicals from Sigma-Aldrich, unless specified otherwise.
IFN-b was provided by M. Noursadeghi (UCL, London, UK), and
nevirapine obtained from the AIDS Research and Reference
Reagent Program (NIAID, Bethesda, USA).
Antibodies to CD4 (Q4120), HIV-1 p24/p55 Gag (38:96K and
EF7) and HIV-1 p17 Gag (4C9), as well as an antiserum to HIV-1
p24/p55 Gag (ARP432), were obtained from the NIBSC Centre for
AIDS Reagents (South Mimms, UK). Anti-CD68 (KP1) was
provided by R. da Silva (University of Oxford, Oxford, UK), anti-
CD81 (M38) by F. Berditchevski (University of Birmingham,
Birmingham, UK), anti-CD81 (1.337) by J. Grove (UCL, London,
UK), anti-CXCR4-Alexa Fluor 488 (12G5) by J. Hoxie (UPenn,
Philadelphia, USA), anti-VSV-G (P5D4) by T. Kreis (UNIGE,
Geneva, Switzerland), and antisera to Env gp120, HIV-1 p17 Gag
(UP595) and Vpu (U2-3) by N. Haigwood (OHSU, Portland, USA),
M. Malim (KCL, London, UK) and K. Strebel (NIAID, Bethesda,
USA), respectively. Anti-HIV-1 p24/p55 Gag (Kal-1) was pur-
chased from Dako (Ely, UK), anti-CD9 (MCA469G) and anti-
TGN46 (AHP500G) from AbD Serotec (Kidlington, UK), anti-
CD18 (MEM-48) and anti-CD3 (MEM-57) from Abcam (Cam-
bridge, UK), anti-c-adaptin (88/Adaptin c), anti-CD3-PerCP (SK7),
anti-CD3 (UCHT1), anti-CD4-FITC (RPA-T4), anti-CD195-PE
(2D7/CCR5), anti-CD14-APC (M5E2) and anti-LAMP-1 (H4A3)
from BD Biosciences (Oxford, UK), anti-actin (I-19) from Santa
Cruz Biotechnology (Santa Cruz, USA), anti-IFN-a/b R2
(MMHAR-2) and mouse IgG2A isotype control (20102) from
R&D Systems (Abingdon, UK), monoclonal and polyclonal anti-Bst-
2 (M15 and B02P, respectively) from Abnova (Taipei, Taiwan),
Alexa Fluor-conjugated antibodies from Life Technologies, and
HRP-conjugated antibodies from Thermo Fisher Scientific.
Plasmids and virus stocks
The Nef-negative HIV-1 molecular clone NL4.3-R3A, here
referred to as R3A-(+), was provided by J. Hoxie (UPenn,
Philadelphia, USA) [47], and used to avoid Nef-specific effects on
Tetherin. To obtain R3A-(2), the Vpu start codon of R3A-(+) was
mutated using the primers 59-CTCTC TATCA AAGCA
GTAAG TAGTA CATGT AGTGC AATCT TTACA AA-
TAT-39 and 59-ATATT TGTAA AGATT GCACT ACATG
TACTA CTTAC TGCTT TGATA GAGAG-39 and the
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent
Technologies, Wokingham, UK) according to the manufacturer’s
instructions. To obtain R3A-Udel, two unique XbaI restriction
sites were introduced into the Vpu gene of R3A-(+) using the
primers 59-GTAAG TAGTA CATGT AATGC AATCT
TTACA AATTC TAGAA ATAGT AGCAT TAGTA GTAGC
AGC-39 and 59-GCTGC TACTA CTAAT GCTAC TATTT
CTAGA ATTTG TAAAG ATTGC ATTAC ATGTA CTACT
TAC-39, and 59-GTATG GTCCA TAGCA CTCAT AGAAT
ATAGG AAAAT ATCTA GACAA AGAAA AATAG ACA-39
and 59-TGTCT ATTTT TCTTT GTCTA GATAT TTTCC
TATAT TCTAT GAGTG CTATG GACCA TAC-39, and the
QuikChange II XL kit as described above. The resulting plasmid
was digested with XbaI (Promega, Southampton, UK) and re-
ligated without the 82 bp fragment of Vpu.
To produce virus stocks from molecular clones, HEK 293T cells
were transfected with proviral DNA using FuGENE HD
(Promega). Culture supernatants were harvested after two days
and cleared of cell debris by centrifugation and filtration
(0.45 mm). Viruses were pelleted through 25% sucrose cushions
for 2 h at 100,000 g and 4uC and resuspended in complete
medium (RPMI 1640, 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin, and 10% human AB serum). Stocks of HIV-1 BaL were
prepared as described previously [24].
p24 ELISA assay
p24 levels in cell-free supernatants from HIV-1-infected cells
were quantified using the HIV-1 p24CA Antigen Capture Assay
Kit (AIDS and Cancer Virus Program, National Cancer Institute,
Frederick, USA), or the QuickTiter HIV Lentivirus Quantitation
Kit (Source BioScience, Nottingham, UK), according to the
manufacturers’ instructions.
Single-cycle infectivity assay
The single-cycle infectivities of virus stocks were determined
using TZM-bl indicator cells (provided by J. Martin-Serrano,
KCL, London, UK). Cells were infected for 2 h at 1,300 g with
dilutions of virus stocks containing 0.5–2 ng of p24 Gag or
reference virus of known titres. b-galactosidase expression was
quantified 24 h later using the Galacto-Star b-Galactosidase
Reporter Gene Assay System (Life Technologies) and a PHER-
Astar Plus microplate reader (BMG LABTECH, Aylesbury, UK).
Single-cycle infectivities of MDM-derived R3A were determined
by incubating TZM-bl indicator cells with cell-free virus-contain-
ing culture supernatants containing 2–5 ng of p24 Gag and
quantifying b-galactosidase expression 24 h later as described
above.
siRNA the next day. Six days later, autologous T cells were co-cultured with the infected MDMs for 6 h, separated from the MDMs, and lysed
immediately (0 days) or incubated for another two days in the presence of 500 nM NVP (2 days). The T cell lysates (T cells), and lysates of the MDMs
(MDMs) used for the experiment, were analysed by western blotting. Note that residual Tetherin levels in the MDMs had to be,5% to see a rescue of
the T cell infection with R3A-(2) and -Udel.
doi:10.1371/journal.ppat.1004189.g009
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Figure 10. Tetherin promotes the transfer of infectious HIV clusters to T cells. (A) R3A-(+), -(2), or -Udel-infected MDMs, or uninfected
control MDMs, were co-cultured with autologous CD4+ T cells for 6 h. As a control, 5 mM NVP was added to parallel MDM-T cell co-cultures. All T cells
were separated from the MDMs, and aliquoted for qPCR and western blot analyses. For qPCR analysis, T cells were lysed immediately, and Gag DNA
levels quantified by qPCR and normalised to GAPDH. The levels of contaminating MDM-derived Gag and GAPDH DNA were subtracted from the total
DNA levels. Graphs for the ‘‘no NVP’’ samples show the means 6 SD of triplicate samples from a representative experiment relative to R3A-(+) (set at
100%). Single values are shown for the ‘‘5 mM NVP’’ samples. For western blot analyses, T cells were lysed immediately (0 days), or after another two
day-incubation (2 days). (B–C) T cells were co-cultured with R3A-infected MDMs for 6 h, separated from the MDMs, fixed, immunostained for p17 Gag
and CD3, and analysed by flow cytometry. (B) shows the results of a representative experiment, and the numbers next to the gates indicate the
proportions of cells with small (16), medium (36), and large (106) p17 Gag clusters. (C) shows the mean proportions of cells with small (16), medium
(36), and large (106) p17 Gag clusters 6 SD of duplicate samples from three donors, normalised to the MDM infection levels. Each donor is
represented by differently shaped data points.
doi:10.1371/journal.ppat.1004189.g010
Figure 11. Tetherin can prevent MDMs from initiating a spreading infection in T cells. (A) R3A-(+), -(2), or -Udel-infected MDMs, or
uninfected control MDMs, were co-cultured with autologous CD4+ T cells for 6 h, the T cells separated from the MDMs and lysed immediately (0
days), or after another one to three day-incubation (1–3 days). Gag DNA levels in the T cells were quantified by qPCR and normalised to GAPDH. As a
control, 500 nM NVP was added to parallel MDM-T cell co-cultures, and to the T cells after the co-culture [(+)+500 nM NVP]. The levels of
contaminating MDM-derived Gag and GAPDH DNA were subtracted from the total DNA levels. Graphs show the means 6 SD of triplicate samples
from a representative experiment relative to R3A-(+) after three days (set at 100%). (B–C) T cells were co-cultured with R3A-infected MDMs for 6 h,
separated from the MDMs and fixed immediately (0 days), or incubated for another five days (5 days). The T cells were immunostained for p24/p55
Gag and CD3, and analysed by flow cytometry. (B) shows the results of a representative experiment, and the numbers above the gates indicate the
proportions of Gag-positive cells. (C) shows the mean proportions of Gag-positive cells 6 SD from three donors.
doi:10.1371/journal.ppat.1004189.g011
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Cells and infections
MDMs were prepared from peripheral blood mononuclear cells
(PBMC), isolated from buffy coats from HIV-negative blood
donors (National Blood Service, Essex, UK), as described
previously [48], and differentiated in complete medium containing
10 ng/ml of M-CSF (R&D Systems, Abingdon, UK) for two days.
Where indicated, seven day-old MDMs were infected with HIV-1
(3 MOI/cell) by spinoculation for 2 h at 1,300 g and cultured for a
further seven days. Unless specified otherwise, the MDMs were
used after 14 days in culture.
To obtain autologous CD4+ T cells, the non-adherent fraction
of the PBMCs was frozen and defrosted after nine days, unless
specified otherwise. The cells were activated for three days with
1 mg/ml lectin from Phaseolus vulgaris (Sigma-Aldrich) and 5 ng/ml
IL-2 (R&D Systems) in complete medium. CD4+ T cells were
isolated using the CD4+ T Cell Isolation Kit (Miltenyi Biotec,
Bisley, UK) according to the manufacturer’s instructions, and
cultured for a further two days in complete medium containing
5 ng/ml IL-2.
For co-cultures of MDMs and autologous CD4+ T cells, 3 T
cells/MDM were added to the MDMs in complete medium and,
unless specified otherwise, incubated for 6 h at 37uC and 5% CO2.
The T cells were separated from the MDMs, residual T cells
washed off with PBS, and all T cells lysed immediately or cultured
in complete medium containing 5 ng/ml IL-2.
Tetherin RNAi
MDMs were transfected with 60 nM Stealth siRNA targeting
Tetherin (oligo ID HSS101115, Life Technologies), or Stealth
siRNA Negative Control Med GC (Life Technologies), using
Lipofectamine RNAiMAX (Life Technologies) according to the
manufacturer’s instructions. Transfection complexes were re-
moved one day after transfection.
DNA/RNA isolations, reverse transcription and
quantitative PCR
Total DNA was isolated from T cells using the DNeasy Blood
and Tissue Kit (QIAGEN, Manchester, UK) according to the
manufacturer’s instructions. 20–40 ng of DNA were used to
quantify the levels of Gag and GAPDH using 500 nM of the
previously characterised primers 59-ACATC AAGCA GCCAT
GCAAA T-39 and 59-ATCTG GCCTG GTGCA ATAGG-39,
and 59-ACCAC AGTCC ATGCA TCACT-39 and 59-GGCCA
TCACG CCACA GITT-39 [49], respectively, the DyNAmo Flash
SYBR Green qPCR Kit (Thermo Fisher Scientific), and a
Mastercycler ep realplex 2 (Eppendorf, Stevenage, UK) with the
following programme: 95uC for 7 min, and 40 cycles at 95uC for
10 s and 65uC for 30 s. Serial dilutions from one experimental
sample were prepared for the standard curve. For MDM-T cell co-
culture experiments, the levels of contaminating MDM-derived
Gag and GAPDH DNA were subtracted from the total DNA
levels. To determine the levels of MDM-derived DNA, medium
only was added to HIV-infected MDMs and subsequently treated
as the co-cultured T cells. MDM-derived Gag DNA levels were
typically between 5 and 27% of the total levels for HIV-1 BaL, and
between 5 and 17% for HIV-1 R3A. MDM-derived GAPDH
levels were max. 2% of the total levels. Gag DNA levels were
normalised to GAPDH.
Total RNA was isolated from cells using the RNeasy Plus Mini
Kit (QIAGEN), and 50 ng of RNA reverse transcribed using the
QuantiTect Reverse Transcription Kit (QIAGEN) according to
the manufacturer’s instructions. qPCR was performed as described
above using 200 nM of IFIT1 and GAPDH primers from the
IFNr qRT-Primer Set (Source BioScience), 200 nM of Bst-2
primers from the RT2 qPCR Primer Assay (QIAGEN), and the
following cycler programme: 95uC for 10 min, 40 cycles at 95uC
for 15 s, 60uC for 30 s and 72uC for 30 s, and 72uC for 10 min.
No reverse transcriptase was added to control samples to confirm
the complete elimination of genomic DNA. IFIT1 and Bst-2 RNA
levels were normalised to GAPDH.
Western blot analysis
For western blot analysis cells were washed in PBS and lysed in
Laemmli Sample Buffer (Sigma-Aldrich) for 10 min at 95uC. The
lysates were separated on SDS-polyacrylamide gels and trans-
ferred to Immobilon-P PVDF membranes (Millipore, Watford,
UK) at 20 V for 1 h under semi-dry blotting conditions. Blots
were quenched in 0.1% Tween/5% non-fat milk/PBS for 1 h at
room temperature, incubated with primary antibody at 4uC
overnight, washed three times with 0.1% Tween/PBS, and
incubated with the appropriate HRP-conjugated secondary
antibody for 1 h at room temperature. After five washes with
0.1% Tween/PBS, membranes were briefly incubated in Super-
Signal West Pico/Dura/Femto Chemiluminescent Substrate
(Thermo Fisher Scientific) and signals detected with Amersham
Hyperfilm ECL (GE Healthcare Life Sciences, Little Chalfont,
UK). For the comparison of Tetherin levels in T cells and MDMs,
cells were lysed in non-reducing Laemmli buffer without
bromophenol blue (10% SDS, 15% glycerol, 0.2 M Tris-HCl
pH 6.8), total protein concentrations determined using the Bio-
Rad DC Protein Assay (Bio-Rad, Hemel Hempstead, UK)
according to the manufacturer’s instructions, and 5 mg protein
used for western blot analysis as described above. All Tetherin
blots were performed under non-reducing conditions and using
the polyclonal Bst-2 antibody B02P. Blots were scanned and
quantified with Fiji.
Immunofluorescence
For immunofluorescence, MDMs were washed with PBS, fixed
in 4% PFA, quenched with 50 mM NH4Cl and permeabilised
with 0.1% Triton X-100/0.5% BSA/6 mg/ml human IgG/PBS.
Cells were labelled for 1.5 h with primary antibodies diluted in
0.5% BSA/6 mg/ml human IgG/PBS, washed in 0.5% BSA/PBS
and incubated for 1 h with appropriate combinations of fluores-
cent secondary antibodies. Samples were washed, DNA stained
with 10 mg/ml Hoechst 33258 in PBS, and coverslips mounted in
Mowiol. Confocal images were acquired with an inverted Leica
TCS SP5 confocal microscope, 636oil objective (NA 1.4) and LAS
AF software, and processed using Fiji. Where indicated live,
unpermeabilised MDMs were incubated for 1 h on ice in complete
medium containing the appropriate primary antibodies before
fixation. For immunostaining of live, permeabilised MDMs, cells
were incubated for 20 min on ice in 0.05% saponin/0.5% BSA/
6 mg/ml human IgG/PBS containing the appropriate primary
antibodies, washed with ice-cold PBS, fixed, and labelled with
secondary antibodies in the presence of 0.1% saponin as described
above. Where indicated, live, permeabilised MDMs were immu-
nostained, fixed, and immunostained with additional primary
antibodies in the presence of 0.1% Triton X-100 as described
above.
Flow cytometry analysis
For flow cytometry analysis of cell surface Tetherin levels on
infected MDMs, cells were incubated for 1 h on ice in complete
medium containing 10 mg/ml polyclonal Bst-2 antibody (B02P).
Cells were washed once with ice-cold PBS, fixed in 4% PFA,
scraped off the tissue culture dish, permeabilised with 0.1%
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saponin/1% human AB serum/6 mg/ml human IgG/2 mM
EDTA/0.05% sodium azide/PBS, labelled for 1 h with a-p24/
p55 rabbit serum (ARP432), washed three times in 0.1% saponin/
1% human AB serum/2 mM EDTA/0.05% sodium azide/PBS,
incubated for 30 min with appropriate Alexa Fluor-conjugated
secondary antibodies, washed three times and analysed on an LSR
II flow cytometer (BD Biosciences). For flow cytometry analysis of
T cells and MDMs following their co-culture, cells were washed
with PBS, fixed in 4% PFA, and immunostained with the
appropriate primary and subtype specific Alexa Fluor-conjugated
secondary antibodies as described above. For flow cytometry
analysis of cell surface proteins on primary CD4+ T cells, cells
were incubated for 30 min at 4uC in 1% FCS/6 mg/ml human
IgG/2 mM EDTA/0.05% sodium azide/PBS, labelled for 1 h at
4uC with primary antibodies conjugated to fluorescent dyes, and
washed three times in 1% FCS/2 mM EDTA/0.05% sodium
azide/PBS. Data were analysed using FlowJo software (TreeStar,
Ashland, USA).
To analyse the proportion of dead cells, primary T cells were
washed with PBS, labelled with Violet Dead Cell Stain (Life
Technologies) according to the manufacturer’s instructions,
washed with PBS, fixed in 4% PFA, and analysed by flow
cytometry.
Statistical analysis
Unless specified otherwise, p values were calculated using an
unpaired Student’s t-test.
Supporting Information
Figure S1 Tetherin localises to the cell surface, TGN,
and IPMCs. (A,B) Untreated MDMs were incubated for 20 min
on ice with 10 mg/ml polyclonal Tetherin (THN) antibody (B02P)
and 2.5 mg/ml anti-TGN46, or with 10 mg/ml monoclonal
Tetherin antibody (M15) and 2 mg/ml anti-CD9, in the presence
of 0.05% saponin. Cells were fixed and labelled with fluorescent
secondary antibodies. Arrowheads point at structures reminiscent
of IPMCs. Double arrows indicate TGN-like staining patterns. All
images are single confocal sections. Scale bars = 10 mm.
(TIF)
Figure S2 Long-term HIV infection of MDMs triggers
an IFN-dependent upregulation of Tetherin. MDMs were
pre-incubated for 30 min at 37uC with 1 mg/ml of IFN-a/b
receptor antibody (IFNR AB), or an isotype-matched control
antibody (control AB), and subsequently infected with R3A-(+), -
(2), or -Udel for seven days in the presence of the same antibodies.
All cells were lysed and analysed by western blotting. Numbers
above the lanes indicate the Tetherin band intensities relative to
uninfected, control antibody-treated MDMs (set at 1).
(TIF)
Figure S3 Tetherin retains mature HIV on MDMs.
MDMs were infected with R3A-(+), -(2), or -Udel for seven days,
fixed, permeabilised, labelled with p24/p55 and p17 Gag
antibodies, stained with fluorescent secondary antibodies, and
analysed by flow cytometry. Uninfected cell populations were left
ungated, infected cell populations gated on the p24/p55 Gag-
positive subpopulations, and the p17 Gag fluorescence was
analysed. (A) shows the results of a representative experiment,
the lines in (B) indicate the average p17 Gag mean fluorescence
intensities (MFI) 6 SD of duplicate samples from four donors
relative to R3A-(+)-infected cells (set at 1). In (B), each donor is
represented by differently shaped data points.
(TIF)
Figure S4 Virological synapses form between HIV-
infected MDMs and autologous T cells. MDMs were
infected with HIV-1 BaL for seven days, co-cultured with
autologous CD4+ T cells for 2.5 h, fixed and immunostained for
the indicated proteins. The lower panels show magnifications of
the boxed areas in the upper panels. Arrows indicate VS. Scale bar
in upper panel = 20 mm, lower panel = 10 mm.
(TIF)
Figure S5 Tetraspanins and integrins localise to the
MDM-T cell VS. (A–C) MDMs were infected with HIV-1 BaL
for seven days, co-cultured with autologous CD4+ T cells for 2.5 h,
fixed and immunostained for the indicated proteins. Arrows
indicate VS. Scale bars = 10 mm.
(TIF)
Figure S6 HIV-1 R3A spreads more efficiently by cell-
cell than by cell-free transmission. Autologous CD4+ T cells
were incubated for 6 h with R3A-(+)-infected MDMs, or with cell-
free supernatants collected from the same MDMs during the
preceding 6 h period. All T cells were collected, and Gag DNA
levels in the T cells quantified by qPCR and normalised to
GAPDH. For cell-cell transmission, the levels of contaminating
MDM-derived Gag and GAPDH DNA were subtracted from the
total DNA levels. Bars represent the means 6 SD of triplicate
samples from a representative experiment relative to cell-free (set
at 1).
(TIF)
Figure S7 Vpu expression in R3A-infected MDMs does
not influence their adhesion to T cells. (A) R3A-(+), -(2), or
-Udel-infected MDMs, or uninfected control MDMs, were co-
cultured with autologous CD4+ T cells for 6 h. T cells were then
washed off the MDMs with PBS, fixed and counted. Bars
represent the mean proportions of recovered T cells 6 SD of
duplicate samples from three donors. (B–E) R3A-infected MDMs,
or uninfected control MDMs, were co-cultured with autologous
CD4+ T cells for 6 h. No T cells were added to uninfected MDMs
as a control. T cells were washed off the MDMs with PBS. The
MDMs were fixed with PFA, immunostained for the T cell marker
CD3, the MDM marker CD68, and HIV-1 p24/p55 Gag in the
presence of 0.1% saponin, and analysed by flow cytometry. (B)
shows CD3/CD68 plots from a representative experiment, and
the numbers within the gates indicate the relative frequencies of
MDMs (set at 1), and T cells that had detached during the staining
procedure and had therefore loosely interacted with MDMs. The
bars in (C) represent the mean ratios of T cells to MDMs 6 SD of
duplicate samples from four donors. (D) shows CD3 plots of
CD68-positive, uninfected or infected MDMs from a representa-
tive experiment, and the gates are set to discriminate between
MDMs without T cells and MDMs that had remained associated
with T cells during the staining procedure, and had therefore
formed tight interactions. (E) shows the mean proportions of
MDMs that had formed tight interactions with T cells 6 SD of
duplicate samples from three donors, and each donor is
represented by differently shaped data points.
(TIF)
Figure S8 R3A-infected MDMs may form transient VS.
(A) MDMs were infected with HIV-1 R3A for seven days, co-
cultured with autologous CD4+ T cells for 2.5 h, fixed and
immunostained for the indicated proteins. Scale bar = 10 mm. (B–
C) Unpermeabilised primary CD4+ T cells were immunostained
for the indicated proteins and analysed by flow cytometry. (B)
shows the results from a representative experiment. The red
graphs represent stained T cells, the grey graphs unstained control
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cells. (C) shows the mean proportions of positive cells 6 SD from
four donors, where each donor is represented by differently shaped
data points.
(TIF)
Figure S9 Western blotting conditions effect Tetherin
quantification. MDMs were stimulated for 24 h with 0–
2,721 U/ml (0–10 ng/ml) IFN-b eight days post isolation from
buffy coats, and lysed in non-reducing Laemmli buffer. Untreated
lysates (non-reduced) and lysates treated with 2-mercaptoethanol
(reduced) were separated on SDS-polyacrylamide gels, and
Tetherin levels were analysed by western blotting.
(TIF)
Figure S10 T cells remain viable after their co-culture
with HIV-infected MDMs. (A) To confirm the reactivity of the
dead cell stain, primary CD4+ T cells from one donor were
incubated for 20 min at 60uC, labelled with dead cell stain, fixed,
and analysed by flow cytometry. Cells were kept at 37uC and
labelled with the same stain (37uC), or left unlabelled (no stain), as
controls. (B–C) R3A-(+), -(2), or -Udel-infected MDMs, or
uninfected control MDMs, were co-cultured with autologous
CD4+ T cells for 6 h. T cells were washed off the MDMs with
PBS, and labelled with a Violet Dead Cell Stain immediately, or
after another 6-, 18-, or 30 h-incubation. The cells were fixed,
immunostained for CD3, and analysed by flow cytometry. (B)
shows the results of a representative experiment, and the numbers
in the top right quadrants indicate the proportions of dead CD3+
cells. (C) shows the mean proportions of dead CD3+ cells 6 SD
from duplicate samples of three donors.
(TIF)
Figure S11 MDMs infected with R3A-(+), -(2) and –Udel
for seven days show similar infection levels. MDMs were
infected with R3A-(+), -(2), or -Udel for seven days. (A–B) The
cells were lysed, and analysed by western blotting. The blots in (A)
and (B) are from parallel cultures of the MDMs used for the cell-
cell transmission experiments shown in Fig. 9B and Fig. 9C,
respectively. (C–D) The cells were fixed, permeabilised, labelled
with p24/p55 Gag antibodies, and stained with fluorescent
secondary antibodies. The proportions of p24/p55 Gag-positive
MDMs were analysed by flow cytometry. (A) shows the results of a
representative experiment, the lines in (B) indicate the means of
duplicate samples from four donors, where each donor is
represented by differently shaped data points. Note that the
analyses shown in (C) and (D) were performed on the same
samples used for Fig. S3.
(TIF)
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